Scott Uretsky1. 1. Wills Eye Institute, Neuro-Ophthalmology Division, Philadelphia, Pennsylvania 19107, USA. uretsx@gmail.com
Abstract
PURPOSE OF REVIEW: Idiopathic intracranial hypertension (IIH) can present with severe loss of vision or with ongoing vision loss despite maximal medical therapy; these situations require aggressive management with surgical interventions. To date, optimal surgical management has not been clearly defined. A review of the recent literature is undertaken to clarify the role of surgical interventions in IIH. RECENT FINDINGS: To date, no prospective, randomized study has been performed comparing lumboperitoneal shunt, ventriculoperitoneal shunt and optic nerve sheath fenestration/decompression. Procedure choice appears to be based on local availability and expertise, as well as the prominence of presenting symptoms. Delay in surgical intervention for fulminant and medically refractory cases leads to worse visual outcomes. SUMMARY: Surgical intervention for IIH will likely be based on local expertise until well designed, multicentered clinical trials clarify which intervention best suits a particular patient.
PURPOSE OF REVIEW: Idiopathic intracranial hypertension (IIH) can present with severe loss of vision or with ongoing vision loss despite maximal medical therapy; these situations require aggressive management with surgical interventions. To date, optimal surgical management has not been clearly defined. A review of the recent literature is undertaken to clarify the role of surgical interventions in IIH. RECENT FINDINGS: To date, no prospective, randomized study has been performed comparing lumboperitoneal shunt, ventriculoperitoneal shunt and optic nerve sheath fenestration/decompression. Procedure choice appears to be based on local availability and expertise, as well as the prominence of presenting symptoms. Delay in surgical intervention for fulminant and medically refractory cases leads to worse visual outcomes. SUMMARY: Surgical intervention for IIH will likely be based on local expertise until well designed, multicentered clinical trials clarify which intervention best suits a particular patient.
Authors: Luisam Tarrats; Gabriel Hernández; José M Busquets; Juan C Portela; Luis A Serrano; Lorena González-Sepúlveda; José R Sánchez-Pérez Journal: Int Forum Allergy Rhinol Date: 2017-04-06 Impact factor: 3.858
Authors: Justin Schwarz; Ali Al Balushi; Sri Sundararajan; Marc Dinkin; Cristiano Oliveira; Jeffrey P Greenfield; Athos Patsalides Journal: Interv Neuroradiol Date: 2020-11-25 Impact factor: 1.610
Authors: Arielle Spitze; Peter Lam; Nagham Al-Zubidi; Sushma Yalamanchili; Andrew G Lee Journal: Indian J Ophthalmol Date: 2014-10 Impact factor: 1.848
Authors: Ryan Ottridge; Susan P Mollan; Hannah Botfield; Emma Frew; Natalie J Ives; Tim Matthews; James Mitchell; Caroline Rick; Rishi Singhal; Rebecca Woolley; Alexandra J Sinclair Journal: BMJ Open Date: 2017-09-27 Impact factor: 2.692